MYCi975 (Nuc-0200975) is an orally active MYC inhibitor that disrupts MYC/MAX interactions, promotes MYC T58 phosphorylation and MYC degradation, and impairs myC-driven gene expression. MYCi975 (NUC-0200975) has strong anti-tumor effect and good tolerance, increasing tumor immune cell infiltration and enhancing tumor sensitivity against PD1 immune studies.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO ≥ 60 mg/mL|
|Related c-Myc Products|
Vpc-70619 is a potent oral active n-myC inhibitor. Vpc-70619 inhibits the binding of n-MyC-Max complex to DNA e-box and exhibits strong inhibitory activity against N-MyC-dependent cell lines and high bioavailability for oral and intrabitoneal administration.
ML327 is a blocker of MYC, which mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition.
10074-G5 is a c-Myc/Max interaction inhibitor, which binds to a different specific binding site (region) of C-Myc than 10054-F4.
10058-F4 is a c-Myc inhibitor that specificallly inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.